Objective: Relapsing polychondritis (RP) is a rare autoimmune inflammatory disease that attacks mainly cartilaginous structures or causes serious damage in proteoglycan-rich structures (the eyes, heart, blood vessels, inner ear). This study shows results regarding the epidemiology, progression, and associations of this highly variable disease by collecting all cases from a 124-million-person-year Central European nationwide cohort. Methods: We used the Hungarian Health Care Database to identify all persons with possible RP infection. We followed patients who had International Classification of Diseases 10th edition code M94.1 at least once in their inpatient or outpatient records between January 1, 2002 and December 31, 2013 in Hungary. We classified these patients into disease severity groups by their drug consumption patterns between January 1, 2010 and December 31, 2013. We analyzed the regional distribution of RP incidences as well. Overall maps of comorbidity are presented with network layouts. Results: We identified 256 patients with RP among cumulatively 11.5 million registered inhabitants. We classified these patients into four severity classes as "extremely mild" (n=144), "mild" (n=22), "moderate" (n=41), and "severe" (n=4). Two additional groups were defined for patients without available drug data as "suspected only" (n=23) and "confirmed but unknown treatment" (n=22). The age and sex distributions of patients were similar to worldwide statistics. Indeed, the overall survival was good (95% confidence interval for 5 years was 83.6%-92.9% and for 10 years was 75.0%-88.3% which corresponds to the overall survival of the general population in Hungary), and the associations with other autoimmune disorders were high (56%) in Hungary. Almost any disease can occur with RP; however, the symptoms of chromosomal abnormalities are only incidental. Spondylosis can be a sign of the activation of RP, while Sjögren syndrome is the most frequent autoimmune association. Regional distribution of incidences suggests arsenic drinking water and sunlight exposure as possible triggering factors.
Intravenous cyclophosphamide and plasmapheresis are used in life-threatening situations, or in organ-threatening disease including acute airway obstruction or glomerulonephritis. 26 A number of biologics targeting the B cells and the pathways of cell-mediated immunity (anti-CD4, anti-CD20, anti-TNF agents, IL-1 receptor antagonist, CTLA4-IgG1 fusion protein, or anti-IL-6 receptor antibody) are applied if RP is not responding to other medical therapy. 27, 28 In this paper, we report yearly incidence rate, sex ratios, prevalence of severity classes, comorbidity network, and possible environmental triggering factors using health care registries of Hungary.
Methods

Database, time interval, and population
Data from the Hungarian Global Financial Healthcare Database (HGFHD) were used to identify all persons (Hungarian residents or foreigners) who were residing and treated in Hungary in the public health care system between January 1, 2002 and December 31, 2013 . The database has cumulatively registered 11.5 million individuals with 124 million person-years of follow-up of hospital admissions and contacts in outpatient clinics. This population has a life expectancy of 72 years for males and 79 years for females where the leading death causes are the diseases of the circulatory system (n=62,979; 50% of the total number of deaths), cancer (n=33,274; 26% of the total number of deaths), and diseases of the respiratory system (n=7,009; 5.53% of the total number of deaths). Each reported visit is marked with one or more diagnoses according to the International Classification of Diseases 10th edition (ICD10). 29 Data in this database are collected primarily for financial purposes, though the diagnoses are always specified by the visited physician, who is responsible for correctness of the data.
The second data source of the study was the Hungarian Drug Consumption Database (HDCD), which registers information about Rx (prescription linked) and reimbursed medicines obtained in pharmacies between January 1, 2010 and December 31, 2013. The main deficiency of HDCD is that it does not concern over the counter and unreimbursed drug obtainment. Furthermore, it does not include drugs taken during inpatient care nor provide information about real medicine consumption.
A unique social security number assigned to all residents in Hungary allows record linkage of databases at the individual level because both databases are maintained by the National Health Insurance Fund.
We constructed a patient pool (n=256) from the HGFHD by selecting people with outpatient or inpatient visits marked with RP (ICD10 = M94.1) either as a primary or as an associated diagnosis code. Some of the patients (n=23) were not considered in the epidemiological statistics because their symptoms had been determined by laboratory, pathology, computed tomography, or magnetic resonance diagnostics, but the disease was not confirmed later by specialists.
Due to the retrospective nature of the study, this study was deemed exempt by Hungarian Ministry of Health legislation regarding encrypted databases for research purposes in Hungary. Databases used in the study contain encrypted patient personal information to protect privacy and provides researchers with anonymous identification numbers. Therefore, patient written informed consent is not required to access the database for research purposes.
Severity classes
We used medication treatment data from HDCD for distinguishing severity levels of the disease. From the combinations 
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of the three main types of drugs (NSAID, steroid, immunosuppressant) 30 and from the time delay between the drug obtainment and the clinical diagnosis of RP, we grouped the observed RP cases into four progression levels. Patients in the study population were classified according to the level of the most severe case in their history in HDCD.
Since HDCD is available for the years 2010-2013, it provides information for the end of the histories of n=211 individuals, which corresponds to 90.6% of the confirmed RP population.
Levels of disease severity and hospitalization length
Two further classes were constructed for the people who either never had a confirmed RP or had no records in the HDCD. The members of these classes were included neither in the severity versus treatment-duration analysis in this Section.
According to the mentioned guidelines, the whole (n=256) RP population was classified as follows:
• Suspected only (n=23): Patients who had M94.1 record in the patient history, but these records were defined by laboratories or pathology or CT without further clinical confirmation. We considered these cases as instances of clinician's suspicion where the result did not support previous assumptions. Therefore, the HDCD records of patients in this class were irrelevant. This class was excluded from severity statistics and analysis.
• Confirmed only (n=22): Patients who did not have records in the drug obtainment database but had clinically confirmed RP diagnoses. This class was excluded from severity statistics and analysis. Here, an earlier level of severity was inferred from the frequency of patient-doctor contacts.
• Confirmed and treated with drugs in HDCD range (n=211): This group was selected by the condition that RP was diagnosed by a clinician and the patient had obtained medicine at least once according to the HDCD. We subdivided this group by treatment patterns into severity groups ranging from extremely mild to severe. In order to confirm that the patient obtained the medicine for RP, we only took those drugs into account which were bought within 30 days after an outpatient/inpatient visit marked with RP diagnosis (ICD10 = M94.1). The severity classes were the following:  0 -extremely mild (n=144): The largest subgroup consisted of patients who met any of the criteria given as follows:  Had an RP diagnosis after the start of HDCD (January 1, 2010) and obtained medicine, but the drug is not classified for RP treatment.
 Obtained an RP-related medicine but before the RP diagnosis. Note that there are no drugs targeting RP exclusively; therefore, the patient can take them for other diseases as well, for example, for other autoimmune diseases.  Patients who were last diagnosed with RP 1 month before the start of HDCD (diagnosed before December 1, 2009 ) and had at least one record in the HDCD. We assumed that the patient either had healed or did not need medical control anymore. Therefore, the progression should have been at a very mild stage.  1 -mild (n=22): Patients who bought NSAIDs but none of the stronger drugs.  2 -moderate (n=41): Patients who obtained NSAID combined with steroid or steroid alone.  3 -severe (n=4): Patients who obtained NSAID combined with steroid and immunosuppressant or who took only steroid in combination with immunosuppressant. We did not observe any patient who obtained only immunosuppressant drugs. We emphasize here that the severity classification reflects the disease progression between January 1, 2010 and December 31, 2013 when drug obtainment records were available. In order to demonstrate the validity of the severity levels, we calculated the number of days (ND) the patients visited their physician or were treated in hospital with RP.
Comorbidity networks
We examined comorbidity patterns in the RP population (n=233). We used ICD10 codes or groups of ICD10 codes to identify diseases in the HGFHD between January with co-occurring disease pairs, we present our findings in a compact network form. 31 The network representation has several advantages: • Data are presented in a figure, where the placement (central, peripheral) and the distances between the objects (more connected ones are closer to each other than the less closely related objects) allow expression of qualitative information.
• Colors can be used to enhance similarity between groups of objects.
• Other graphical effects (eg, width of lines) help the readers to compare the intensity of relations between objects.
• The representation is more compact and visual, which allows finding hidden or nontrivial patterns with the human eye. We present two different statistics for diseases appearing together in patients with confirmed RP diagnosis (population: n=233). The two versions correspond to two time ranges where we consider diseases to be co-occurring. For the first statistics, which we denote as lifetime comorbidity (LC), we considered all ICD10 codes that occurred during the whole time window of HGFHD and linked two diseases if they occurred in the same person without time restriction (Figure 1 ). This definition allowed us to observe possible long-term consequences or preliminary indicators. The other definition that we refer to as same day comorbidity (SDC) aims to shed light on closer connections between diagnoses by restricting the co-occurrence relation for the same person and for the same day ( Figure 2 ). Note that if a patient had several visits on the same day at different places, observed diagnoses from all of the visits were considered to be co-occurring. Inpatient sessions were counted as their last-day event regardless of the length of the session. For reference, we provide the data in table form as well (Tables 2 and 3 ). We encourage the readers to take their own calculations by providing the data in excel format as downloadable Supplementary Table S2 as well.
Results
Prevalence, incidence, mortality, and distribution by age and sex
In Hungary, which is a Central European country with approximately ten million inhabitants, 256 patients were diagnosed with RP (ICD10 = M94.1) in the period from January 1, 2002 to December 31, 2013. In 233 cases, the diagnosis was confirmed by a clinician specialist, which corresponds to a 0.020 prevalence ratio per 1,000 of the cumulative insured patient pool in the 12-year-long time interval of the study (n=11.439 million, where ∼100,000/ year new patients were registered and ∼100,000/year patients exited from the system). Figure 3 32 We calculated the overall survival (OS) for three different time lengths with the Kaplan-Meier formula, 33 and the 95% confidence intervals (CIs) were calculated according to the logarithmic transformation of Link. 34 We provide the Hazard ratio analysis in the Supplementary material. The OS for 3 years was 93% (CI =89.7-96.5), for 5 years was 88% (CI =83.6-92.9), and for 10 years was 81% (CI =75.0-88.3).
In our pool, most of the patients with RP were middle aged. As Figure 4 shows, the ratio of patients who belonged to the 40-60 age group was 43%, although the age structure was rather shifted toward the older ages. The youngest patient was 4 years old, and the eldest was 93 years old. The sex ratios for all age groups show that females and males are affected equally by RP (P.0.05 for each age group, P=0.16 for the total population). This is not typical of autoimmune diseases, since females are more affected by a large number of autoimmune diseases. 35 
Levels of disease severity and hospitalization length
We inferred the most severe status of RP in the period from 2010 to 2013 for the patients from drug consumption. From this analysis, we excluded individuals without confirmed RP (n=23) and people without any record in the drug consumption database (n=22). In the rest of the population (n=211), the extremely mild condition was dominant (68%), where no special drugs were applied. At higher progressed status (number of patients: n=67), drugs were involved in the treatment: NSAIDs, steroids, and immunosuppressant medicines. Immunosuppressants were used for the most severe cases (n=4), steroids at the moderate level (n=41), and NSAIDs for mild RP (n=22). Note that at higher levels, combinations of these drugs were used. Figure 5 illustrates the drug consumption habits in mild, moderate, and severe patient groups. Most of the patients combined NSAIDs with steroids, and those who reached the highest level (taking immunosuppressants) had all been through some of the earlier stages. For each group, we provide basic epidemiological statistics in Table 1 . Table 1 presents the average and the standard deviations of ND for each group. Since the distribution of ND is highly skewed, we also included the first, second, and third quartile values. The length of hospitalization shows an increasing tendency as the disease progresses to more severe forms ( Figure 6 ). There are outliers in each group due to complicated comorbidities (higher ND) or very effective drug treatments (lower ND).
Typical diseases occurring with RP
In patients with RP, several kinds of diseases appeared, mainly on a different day than when RP was diagnosed. We describe here the most frequent diseases (ICD10 codes are provided 
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in Table S1 for the named diseases). For each disease, we list two proportions of the patients with RP. The first number represents the relative frequency of the LC in the RP population, and the second percentage indicates the SDC. Both proportions result from the fraction where the numerator is the number of individuals diagnosed with the disease in question and the denominator is the population size of persons with confirmed RP (n=233).
The five most common LCs were hypertonia (LC =77%, SDC =25%), spondylosis (LC =67%, SDC =12%), disorders of refraction and accommodation (LC =67%, SDC =5%), back pain (LC =55%, SDC =7%), and other intervertebral disc disorders (LC =54%, SDC =15%). Among patients with RP, thyroid dysfunction (LC =25%, SDC =4%) and type 2 diabetes (LC =16%, SDC =5%) were detected. More than a quarter of the patients (LC =27%, SDC =4%) were diagnosed with some kind of malignant cancer (lung, skin, breast, or colorectal cancer) in the examined time range. In Hungary, 56% of patients with RP were registered with another autoimmune disease at least once in the HGFHD. Most often, persons were affected by Sjögren syndrome (LC =26%, SDC =12%), rheumatoid arthritis (RA) (LC =20%, SDC =5%), and systemic lupus erythematosis (LC =6%, SDC =3%). Some of the autoimmune diseases were diagnosed typically by different specialists; therefore, the LC and SDC ratios were very different. The three most frequent diseases of this type were thyrotoxicosis (LC =9%, SDC =2%), iridocyclitis (LC =9%, SDC ,1%), and psoriasis (LC =6%, SDC ,1%).
Respiratory infections like sinusitis, rhinitis, bronchitis, influenza, and pneumonia were also very common during the lifetime of the patients (LC =48%, SDC =3%). However, SDC was relatively low indicating a weak connection with RP. A similar contrast was observed for common infectious conjunctivitis (LC =37%, SDC =4%). More than 30% of the patients were registered in HGFHD with at least one of the following conditions: coxarthrosis, dermatitis, ischemic heart disease, lipoprotein disorders, depression, and anxiety problems.
In order to shed light on the interplay between the cooccurring diseases, 36 we constructed the LC network and the SDC network. In these networks, diseases are represented by points (nodes). Point pairs are connected if there is at least one person affected by both diseases. The links between the nodes are weighted with the number of patients who were diagnosed with the disease pair. In the visual representations of these networks in Figures 1 and 2 , we show only links with the largest weights and where the co-occurrence rate is significantly (95% CI) higher than it would be, assuming independent random coincidence. We did not include in the For example, the cell in the row indicated by "1" and in the column indicated by "7" shows that we found 28 patients with both malignant neoplasms (serial number "1") diagnosed anytime during the 12-year follow-up and mental, behavioral, and neurodevelopmental disorders (serial number "7") diagnosed anytime during the 12-year follow-up. For compactness, column headings contain only the serial numbers of the disease groups from the first column. The * indicates disease groups, from where some of the diseases are subtracted to list them separately. For example, from the ICD10 section H60-H95, one disease (H61) is listed separately due to high prevalence; therefore, the prevalence values for H60-H95* group do not count cases of H61 but only cases with any other disease with ICD10 code between H60 and H95. Abbreviations: RP, relapsing polychondritis; ICD10, International Classification of Diseases 10th edition. Number of patients 6 6 Females Males 0 network incidental diseases that are listed with ICD10 codes from chapters "Certain infectious and parasitic diseases" and "Injury, poisoning and certain other consequences of external causes". Detailed co-occurrence statistics are given in Tables  2 and 3 . We advise the readers to look at the networks as a large scale map of the landscape of co-occurring diseases, while for interesting details, they can refer to the tables which present exact numbers. Further analysis is possible with the electronic Supplementary Table 2 and S3.
Discussion
The retrospective analysis with the Hungarian Health Care Database is inevitably tied to the coding system of the International Classification of Diseases. Though the diagnoses are those recorded by treating physicians in the routine practice of care, incidental misdiagnoses or errors in the coding procedure may influence the results. Another possible reason for underestimating the incidence and prevalence is that the HGFHD does not register visits in primary care and visits without any public financial support. We expect that the very low number of private clinics perform a negligible portion of treatments. We also expect that patients with sound manifestations of RP are likely to come to the attention of specialists even if care is initially provided by a primary care practitioner.
Based on the medical profession of the treating divisions, we identified 23 patients out of 256 who were registered with RP, where the diagnosis was probably only a suspicion. This indicates a 10% false-positive error in the Hungarian registerbased prevalence. However, this estimated error rate is not necessarily applicable for other diseases. Frequent symptoms are probably registered more reliably. Indeed, other factors are known to cause errors in public health care databases, for example, administrative rules induce an overestimation of hypertension. The detailed analysis of data accuracy in registers needs deep knowledge of each disease and the ICD10 coding algorithms in individual institutes. In the co-occurrence analysis, we did not carry out accurate analysis of other diseases, and prevalence numbers were reported without any corrections. The estimation of false-positive error and false-negative error could be improved by medical chart review of the population. 
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and females equally, and it can appear any time from early childhood until the end of late adulthood. The most affected age group is the middle-aged population. The simple overall mortality ratio of RP in Hungary was 12.9% as 30 patients died during the 12-year-long examination period. The exact cause of death is not always recorded in the HGFHD. Therefore, we do not have any reliable data about 16 cases of deaths. In 14 cases where data are available, RP was not registered as the cause of death. However, from the last premortem 30-day records, we raise the possibility that in two cases, fulminant RP could be the reason of loss of life. In one of these cases, unspecified contracted kidney was observed, and in the other case, acute respiratory failure was the last diagnosis. The survival rates in Hungary are significantly better than the worldwide rates reported by Michet et al. 4 The 5-year survival rate was reported to be 66%-74% (45% with co-occurring systemic vasculitis), which is below the lower confidence limit of 83.6% inferred from Hungarian data. The 10-year survival rate was 55% around the globe, which is less than the lower confidence limit of 75% in Hungary. The good Hungarian survival values can be related with the severity distribution, where only four cases out of 211 were in severe state and 144 cases in the extremely mild (no reason for applying any special drugs) state. Note that the OS rates of RP correspond to the rates for the general Hungarian population (5-year OS =89%, 10-year OS =79%).
Among patients with RP in Hungary, the most common comorbidity is hypertonia, which is probably the consequence of the age distribution of the RP population. The second comorbidity is spondylosis surely associated with RP. It can warn a physician in practice about the activation of RP. More than half of the patients with RP have another concurrent Groups of progression levels 
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autoimmune disease. This comorbidity ratio is higher than the earlier reported 25%-35%. 3, 16 We suspect that this difference may be related to the low mortality rate in the Hungarian cohort, which allows time for other autoimmune diseases to develop in affected patients. According to the marked variability of manifestations of RP, several other comorbidities were diagnosed in the time interval of the study. Diseases of the musculoskeletal system and connective tissue dominate the comorbidity networks, though diseases of the eye and adnexa, diseases of the circulatory system, and diseases of the respiratory system are characteristic groups as well, besides endocrine, nutritional, and metabolic diseases. Malignant cancer in more than a quarter of the RP population indicates a disorder in the immune system; all kinds of cancers can appear with RP. Because of the observed high rate of osteoporosis, we recommend osteodensitometry screening before RP therapy. We have not seen any significant connection with pregnancy, childbirth, and the puerperium. The low co-occurrence with congenital malformations, deformations, and chromosomal abnormalities is also worth noting.
Regional distribution of RP patients 
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We identified treatment patterns from drug consumption data, and we classified patients into severity classes accordingly. The number of visiting days (indicated by ND) seems to be on average higher for more severe cases. Indeed, we cannot determine the effectiveness of the therapies. The available short time interval of drug usage does not allow us to study long-term differences between NSAID, steroid, or immunosuppressant therapies. However, some patients (n=20) with earlier frequent hospital admissions (number of records with RP in HGFHD is higher than ten) were not diagnosed later on, indicating some successful therapies, but in these cases, drug usage data are not available for the time interval of the earlier frequent visits. Hence, these patients are included in the extremely mild class.
We close our discussion with an open question on the possible triggering effects of RP. Figures 7 and 8 present the standardized regional distribution of patients with RP in Hungary. The highest morbidity rate is observed in the Southern Great Plain region, where effects from ultraviolet sunshine and toxic agents in drinking water are higher than in other regions. This geographical coincidence hints for possible environmental triggers of RP as higher arsenic component 39 in drinking water and intensive sunlight exposure.
Conclusion
We present for the first time a nationwide epidemiology of RP with detailed comorbidity statistics. In Hungary, the survival rate is good, and most of the RP cases are diagnosed in less severe stage. The presented data can help to better understand this complex disease and improve the worldwide survival rate of patients with RP.
Supplementary materials Hazard ratio analysis
The Kaplan-Meier approach presented in the main text of the paper provides a cumulative view of the survival rate of the disease. Another frequently used approach is to look at the hazard function, which assesses the instantaneous risk of death at a point of time, conditional on survival at that time.
The hazard ratio modeling examines the relationship between survival and one or more predictors. We calculated the hazard ratios for the relapsing polychondritis survival with the Cox proportional hazards ratio model 1 using the age groups of the patients as a possible predictor variable. 2 The baseline hazard function with a monotonic increasing trend is shown in Figure S1 . The hazard ratio coefficient is 1.8 (95% confidence interval =1.36-2.38) which is significantly larger than 1 (P=3e-5), meaning that age is a significant factor in the hazard of death.
In Figure S2 , we examine the estimated distribution of survival times, and how the estimated survival depends upon age. Each estimate is accompanied by a point-wise 95% confidence envelope. The survival drops much faster for patients in the older age groups. Anxiety problems A00-B99
Certain infectious and parasitic diseases S00-T88
Injury, poisoning and certain other consequences of external causes
